Neurofilaments as Biomarkers of Disease Activity and Treatment Response in Spinal Muscular Atrophy
European Journal of Neurology · 2026-11 · 33 (11)
DOI: 10.1111/ene.70797 ↗Abstract
ABSTRACT Background Neurofilament light chain (NfL) has been increasingly used in spinal muscular atrophy (SMA) to monitor disease progression and treatment response. Aims We assessed plasma NfL before and after treatment with all three available therapies and in relation to SMA type, age, and functional level. Methods We included all consecutive individuals with SMA who initiated treatment or switched from one treatment to another in whom plasma samples were available at baseline and 12 months post‐treatment. Results Our study included 73 individuals, with Type I ( n = 13), II ( n = 19), III ( n = 33), IV SMA ( n = 1) or individuals diagnosed before clinical onset ( n = 7); 52/73 were treatment naïve and 21 were included at the time of switching to a new treatment. Mean age at baseline was 17 years, ranging from 0 to 47. At baseline, the NfL levels ranged from 4 to 2682 pg/mL. The overall 12‐month changes ranged from −2582.3 to 112 pg/mL. A significant decrease in NfL over time ( p < 0.001) was observed. Age was the strongest predictor of the magnitude of NfL reduction. The reduction was greatest in children < 2 years (83%), with progressively smaller reductions in older age groups. SMN2 copy number and SMA type had no significant interactions. Comparison among treatments was challenging because of cohorts' composition; in adults, risdiplam and nusinersen showed similar magnitudes of NfL changes. Conclusions Our findings expand the literature on NfL in SMA, providing additional data of their changes in response to all three therapies and across a wide spectrum of age and severity.
EUVIMED